William Blair downgraded Charles River Laboratories to market perform from outperform citing a likely decline in early-stage R&D spending from large pharmaceutical companies. Analysts Max Smock and Christine Rains said that they are concerned about the near-term outlook for the contract research organization "given our view that in light of the

William Blair downgraded Charles River (CRL) to Market Perform from Outperform without a price target “There is simply too much working against Charles River in the near term to make the stock interesting,